Anal fistula medical therapy: Difference between revisions

Jump to navigation Jump to search
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Template:Anal fistula}}
{{Template:Anal fistula}}
{{CMG}} {{AE}} {{MKK}}
{{CMG}}, {{AE}}{{MKK}}
==Overview==
==Overview==
Pharmacotherapy used in [[anal fistula]] depends upon the location and symptoms of patient. [[Antibiotics]] are used in patient with comorbities like [[immunosuppression]], [[diabetes]], extensive [[cellulitis]], [[Prosthetic devices|prosthetic]] devices and high risk [[cardiac]] patients. [[Antipyretics]] and [[analgesic]] for symptomatic relief of [[pain]] and [[fever]]. Treatment of underlying causes is important to treat recurrent [[anal fistulas]].
Pharmacotherapy used in anal fistula depends upon the location and symptoms of patient. [[Antibiotics]] are used in patient with comorbities like [[immunosuppression]], [[diabetes]], extensive [[cellulitis]], [[Prosthetic devices|prosthetic]] devices and high risk [[cardiac]] patients. [[Antipyretics]] and [[analgesic]] for symptomatic relief of [[pain]] and [[fever]]. Treatment of underlying causes is important to treat recurrent anal fistulas.


==Pharmocotherapy==
==Pharmocotherapy==
*Empiric therapy for [[anal fistula]] depends on following factors:<ref name="urlwww.fascrs.org">{{cite web |url=https://www.fascrs.org/sites/default/files/downloads/publication/clinical_practice_guideline_for_the_management_of_anorectal_abscess_fistula-in-ano_and_rectovaginal_fistula.pdf |title=www.fascrs.org |format= |work= |accessdate=}}</ref>
*Empiric therapy for anal fistula depends on following factors:<ref name="urlwww.fascrs.org">{{cite web |url=https://www.fascrs.org/sites/default/files/downloads/publication/clinical_practice_guideline_for_the_management_of_anorectal_abscess_fistula-in-ano_and_rectovaginal_fistula.pdf |title=www.fascrs.org |format= |work= |accessdate=}}</ref>
**Location of [[anal fistula]].
**Location of anal fistula.
**If the patient shows signs and symptoms of [[abscess]].
**If the patient shows signs and symptoms of [[abscess]].
*Main stay of therapy is surgical management but [[antibiotics]] are given in the following condition:<ref name="pmid15933794">{{cite journal |vauthors=Whiteford MH, Kilkenny J, Hyman N, Buie WD, Cohen J, Orsay C, Dunn G, Perry WB, Ellis CN, Rakinic J, Gregorcyk S, Shellito P, Nelson R, Tjandra JJ, Newstead G |title=Practice parameters for the treatment of perianal abscess and fistula-in-ano (revised) |journal=Dis. Colon Rectum |volume=48 |issue=7 |pages=1337–42 |year=2005 |pmid=15933794 |doi=10.1007/s10350-005-0055-3 |url=}}</ref><ref name="pmid9236458">{{cite journal |vauthors=Dajani AS, Taubert KA, Wilson W, Bolger AF, Bayer A, Ferrieri P, Gewitz MH, Shulman ST, Nouri S, Newburger JW, Hutto C, Pallasch TJ, Gage TW, Levison ME, Peter G, Zuccaro G |title=Prevention of bacterial endocarditis. Recommendations by the American Heart Association |journal=Circulation |volume=96 |issue=1 |pages=358–66 |year=1997 |pmid=9236458 |doi= |url=}}</ref>
*Main stay of therapy is surgical management but [[antibiotics]] are given in the following condition:<ref name="pmid15933794">{{cite journal |vauthors=Whiteford MH, Kilkenny J, Hyman N, Buie WD, Cohen J, Orsay C, Dunn G, Perry WB, Ellis CN, Rakinic J, Gregorcyk S, Shellito P, Nelson R, Tjandra JJ, Newstead G |title=Practice parameters for the treatment of perianal abscess and fistula-in-ano (revised) |journal=Dis. Colon Rectum |volume=48 |issue=7 |pages=1337–42 |year=2005 |pmid=15933794 |doi=10.1007/s10350-005-0055-3 |url=}}</ref><ref name="pmid9236458">{{cite journal |vauthors=Dajani AS, Taubert KA, Wilson W, Bolger AF, Bayer A, Ferrieri P, Gewitz MH, Shulman ST, Nouri S, Newburger JW, Hutto C, Pallasch TJ, Gage TW, Levison ME, Peter G, Zuccaro G |title=Prevention of bacterial endocarditis. Recommendations by the American Heart Association |journal=Circulation |volume=96 |issue=1 |pages=358–66 |year=1997 |pmid=9236458 |doi= |url=}}</ref>
Line 18: Line 18:
**[[Antipyretics]] and [[analgesics]] like [[acetaminophen]], and [[Ibuprofen]].
**[[Antipyretics]] and [[analgesics]] like [[acetaminophen]], and [[Ibuprofen]].
==Treatment of underlying cause==
==Treatment of underlying cause==
*Treatment of [[anal fistula]] with [[Crohns disease|Crohns]] diseases:
*Treatment of anal fistula with [[Crohns disease|Crohn's]] diseases:
**Anti-[[tumour necrosis factor]] α antibody, [[infliximab]] is the first line of treatment.<ref name="pmid16611273">{{cite journal |vauthors=Sands BE, Blank MA, Diamond RH, Barrett JP, Van Deventer SJ |title=Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study |journal=Aliment. Pharmacol. Ther. |volume=23 |issue=8 |pages=1127–36 |year=2006 |pmid=16611273 |doi=10.1111/j.1365-2036.2006.02878.x |url=}}</ref><ref name="pmid14985485">{{cite journal |vauthors=Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ |title=Infliximab maintenance therapy for fistulizing Crohn's disease |journal=N. Engl. J. Med. |volume=350 |issue=9 |pages=876–85 |year=2004 |pmid=14985485 |doi=10.1056/NEJMoa030815 |url=}}</ref><ref name="pmid19750568">{{cite journal |vauthors=Taxonera C, Schwartz DA, García-Olmo D |title=Emerging treatments for complex perianal fistula in Crohn's disease |journal=World J. Gastroenterol. |volume=15 |issue=34 |pages=4263–72 |year=2009 |pmid=19750568 |pmc=2744181 |doi= |url=}}</ref>
**Anti-[[TNF-α|tumour necrosis factor α]] antibody, [[infliximab]] is the first line of treatment.<ref name="pmid16611273">{{cite journal |vauthors=Sands BE, Blank MA, Diamond RH, Barrett JP, Van Deventer SJ |title=Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study |journal=Aliment. Pharmacol. Ther. |volume=23 |issue=8 |pages=1127–36 |year=2006 |pmid=16611273 |doi=10.1111/j.1365-2036.2006.02878.x |url=}}</ref><ref name="pmid14985485">{{cite journal |vauthors=Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ |title=Infliximab maintenance therapy for fistulizing Crohn's disease |journal=N. Engl. J. Med. |volume=350 |issue=9 |pages=876–85 |year=2004 |pmid=14985485 |doi=10.1056/NEJMoa030815 |url=}}</ref><ref name="pmid19750568">{{cite journal |vauthors=Taxonera C, Schwartz DA, García-Olmo D |title=Emerging treatments for complex perianal fistula in Crohn's disease |journal=World J. Gastroenterol. |volume=15 |issue=34 |pages=4263–72 |year=2009 |pmid=19750568 |pmc=2744181 |doi= |url=}}</ref>
*Treatment of anal fistula with [[Tuberculosis]]:<ref name="pmid18760061">{{cite journal |vauthors=Bokhari I, Shah SS, Inamullah, Mehmood Z, Ali SU, Khan A |title=Tubercular fistula-in-ano |journal=J Coll Physicians Surg Pak |volume=18 |issue=7 |pages=401–3 |year=2008 |pmid=18760061 |doi=06.2008/JCPSP.401403 |url=}}</ref><ref name="pmid19623062">{{cite journal |vauthors=Donoghue HD, Holton J |title=Intestinal tuberculosis |journal=Curr. Opin. Infect. Dis. |volume=22 |issue=5 |pages=490–6 |year=2009 |pmid=19623062 |doi=10.1097/QCO.0b013e3283306712 |url=}}</ref>
*Treatment of anal fistula with [[tuberculosis]]:<ref name="pmid18760061">{{cite journal |vauthors=Bokhari I, Shah SS, Inamullah, Mehmood Z, Ali SU, Khan A |title=Tubercular fistula-in-ano |journal=J Coll Physicians Surg Pak |volume=18 |issue=7 |pages=401–3 |year=2008 |pmid=18760061 |doi=06.2008/JCPSP.401403 |url=}}</ref><ref name="pmid19623062">{{cite journal |vauthors=Donoghue HD, Holton J |title=Intestinal tuberculosis |journal=Curr. Opin. Infect. Dis. |volume=22 |issue=5 |pages=490–6 |year=2009 |pmid=19623062 |doi=10.1097/QCO.0b013e3283306712 |url=}}</ref>
**If the patient is having recurrent [[fistula]] and fail to respond to standard therapy then, [[Tuberculosis]] should be suspected.
**If the patient is having recurrent [[fistula]] and fail to respond to standard therapy then, [[tuberculosis]] should be suspected.
**Anti-[[tuberculous]] drugs are the first line treatment.
**Anti-[[tuberculous]] drugs are the first line treatment.



Latest revision as of 20:46, 13 February 2018

Anal fistula Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Anal fistula from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Diagnostic study of choice

Laboratory Findings

X Ray

Electrocardiogram

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Anal fistula medical therapy On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Anal fistula medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Anal fistula medical therapy

CDC on Anal fistula medical therapy

Anal fistula medical therapy in the news

Blogs on Anal fistula medical therapy

Directions to Hospitals Treating Anal fistula

Risk calculators and risk factors for Anal fistula medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]

Overview

Pharmacotherapy used in anal fistula depends upon the location and symptoms of patient. Antibiotics are used in patient with comorbities like immunosuppression, diabetes, extensive cellulitis, prosthetic devices and high risk cardiac patients. Antipyretics and analgesic for symptomatic relief of pain and fever. Treatment of underlying causes is important to treat recurrent anal fistulas.

Pharmocotherapy

Treatment of underlying cause

References

  1. "www.fascrs.org" (PDF).
  2. Whiteford MH, Kilkenny J, Hyman N, Buie WD, Cohen J, Orsay C, Dunn G, Perry WB, Ellis CN, Rakinic J, Gregorcyk S, Shellito P, Nelson R, Tjandra JJ, Newstead G (2005). "Practice parameters for the treatment of perianal abscess and fistula-in-ano (revised)". Dis. Colon Rectum. 48 (7): 1337–42. doi:10.1007/s10350-005-0055-3. PMID 15933794.
  3. Dajani AS, Taubert KA, Wilson W, Bolger AF, Bayer A, Ferrieri P, Gewitz MH, Shulman ST, Nouri S, Newburger JW, Hutto C, Pallasch TJ, Gage TW, Levison ME, Peter G, Zuccaro G (1997). "Prevention of bacterial endocarditis. Recommendations by the American Heart Association". Circulation. 96 (1): 358–66. PMID 9236458.
  4. Sands BE, Blank MA, Diamond RH, Barrett JP, Van Deventer SJ (2006). "Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study". Aliment. Pharmacol. Ther. 23 (8): 1127–36. doi:10.1111/j.1365-2036.2006.02878.x. PMID 16611273.
  5. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ (2004). "Infliximab maintenance therapy for fistulizing Crohn's disease". N. Engl. J. Med. 350 (9): 876–85. doi:10.1056/NEJMoa030815. PMID 14985485.
  6. Taxonera C, Schwartz DA, García-Olmo D (2009). "Emerging treatments for complex perianal fistula in Crohn's disease". World J. Gastroenterol. 15 (34): 4263–72. PMC 2744181. PMID 19750568.
  7. Bokhari I, Shah SS, Inamullah, Mehmood Z, Ali SU, Khan A (2008). "Tubercular fistula-in-ano". J Coll Physicians Surg Pak. 18 (7): 401–3. doi:06.2008/JCPSP.401403 Check |doi= value (help). PMID 18760061.
  8. Donoghue HD, Holton J (2009). "Intestinal tuberculosis". Curr. Opin. Infect. Dis. 22 (5): 490–6. doi:10.1097/QCO.0b013e3283306712. PMID 19623062.

Template:WH Template:WS